Skip to main content
SpringerLink
Log in

Autoimmune and Antitumor Consequences of Antibodies Against Antigens Shared by Normal and Malignant Tissues

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

There is now a considerable body of information documenting the autoimmune consequences of antibodies induced by growing malignancies, or by passively administered and actively induced antibodies, in cancer patients against antigens shared by normal and malignant tissues. This provides a rich source of information addressing the consequences of autoantibodies against a range of antigens. Antibodies against cell-surface or intracellular antigens in the central nervous system (CNS) or on epithelial surfaces of normal tissues do not generally result in autoimmunity, but the same types and titers of antibodies against cell surface antigens in the subepidermal skin, peripheral nerves, blood, or vascular sites such as the spleen and bone marrow readily induce autoimmunity. The blood brain barrier of the CNS and apical antigen expression and the basement membrane in epithelial tissues, may protect these sites from antibody induced damage. Cancer cells, however, are protected by neither unidirectional antigen expression nor basement membranes. Vaccine induced antibodies against a variety of cancer cell surface antigens have been associated with prevention of tumor recurrence in preclinical models and in vaccinated cancer patients, in the absence of demonstrable autoimmunity. This forms the basis for a series of ongoing Phase III trials with single or polyvalent antigen cancer vaccines designed for optimal antibody induction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. Curr Opin Immunol 9:709-16, 1997

    Google Scholar 

  2. Dighiero G, Lymberi P, Guilbert B, Ternynck T, Ayrameas S: Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann N Y Acad Sci Autoimmunity 475:135-145, 1986

    Google Scholar 

  3. Allison AC: Autoimmune diseases: Concepts of pathogenesis and control. Autoimmunity 4:91-139, 1977

    Google Scholar 

  4. Roitt I, Brostoff J, Male D: Autoimmunity and autoimmune disease. Immunology 28:367-377, 1998

    Google Scholar 

  5. Anhalt GJ, Kim SC, Stanley JR: Paraneoplastic pemphigus: An autoimmune microcutaneous disease associated with neoplasia. N Engl J Med 323:1729-1735, 1990

    Google Scholar 

  6. Dalmau JO, Posner JB: Neurological paraneoplastic syndromes. Prog Clin Neurosci 4:443-453, 1998

    Google Scholar 

  7. Dalmau J, Gultekin HS, Posner JB: Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology. Brain Pathol 9:275-284, 1999

    Google Scholar 

  8. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre, JY: Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 45:162-167, 1999

    Google Scholar 

  9. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, Garcia de Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX: Anti-Hu antibodies in patients with small cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol 15:2866-2872, 1997

    Google Scholar 

  10. Tora M, Graus F, Bolos C, Real FX: Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy-associated Hu antigens in small-cell lung cancers and neuroblastomas. Neurology 48:735-741, 1997

    Google Scholar 

  11. Livingston PO: The case for melanoma vaccines that induce antibodies. In Molecular Diagnosis. Prevention and Treatment of Melanoma, JM Kirkwood (ed.) New York, Marcel Dekker 1998, pp 139-157

    Google Scholar 

  12. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Helling F, Ritter G, Oettgen HF, Old LJ: Improved survival in AJCC stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994

    Google Scholar 

  13. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981

    Google Scholar 

  14. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP: Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival. J Natl Cancer Inst 85:2012-2018, 1993

    Google Scholar 

  15. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KW, Livingston PO: Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int J Cancer 73:42-49, 1997

    Google Scholar 

  16. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood grouprelated antigens. Int J Cancer 73:50-56, 1997

    Google Scholar 

  17. Zhang S, Zhang HS, Reuter VE, Lloyd KO, Scher H, Livingston PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4:295-302, 1998

    Google Scholar 

  18. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry: III Protein antigens. Clin Cancer Res 4:2669-2676, 1998

    Google Scholar 

  19. Hamilton WB, Helling F, Lloyd KO, Livingston PO: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 53:566-573, 1993

    Google Scholar 

  20. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor gene expression in estrogen-positive and negative human breast cancer cell lines. Mol Endocrinol 1:216-223, 1987

    Google Scholar 

  21. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993

    Google Scholar 

  22. Livingston PO, Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer. Part II: Previous experience and future plans. Cancer Immunol Immunother 45:10-19, 1997

    Google Scholar 

  23. Hamilton WB, Helling F, Livingston PO: Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin. Proc AACR 34:491, 1993

    Google Scholar 

  24. Helling F, Livingston PO: Ganglioside conjugate vaccines. In: Molecular and Chemical Neuropathology, vol. 21, New York, Humana Press 1994, pp 299-309

    Google Scholar 

  25. Gendler, SJ: Molecular cloning and expression of human tumor associated polymorphic epithelial mucin. J Biol Chem 265:15286-15293, 1990

    Google Scholar 

  26. Carrato C, Balague C, De Bolos C, Gonzalez E, Gambus G, Planas J, Perini JM, Andreau D: Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 107:160-172, 1994

    Google Scholar 

  27. Merritt WD, Taylor BJ, Der-Minassian V, Reaman GH: Coexpression of GD3 ganglioside with CD45RO in resting and activated human T lymphocytes. Cell Immunol 173:131-148, 1996

    Google Scholar 

  28. Singhal AK, Fohn M, Hakomori S: Induction of Tn (a-Nacetylgalactosamine-O-serine/threoninine) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 50:4308-4314, 1990

    Google Scholar 

  29. Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty RR, Reddish M, Gandhi SS, Longenecker BM, Lloyd KO, Livingston PO: Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55:3364-3368, 1995

    Google Scholar 

  30. Taylor-Papdimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani R, Bodmer WF: Monoclonal antibodies to epithelium specific components of the milk fat globule membrane: Production and reactions with cells in culture. Int J Cancer 28:17-21, 1981

    Google Scholar 

  31. Scheinberg DA, Chapman PB: Therapeutic applications of monoclonal antibodies for human disease. In Monoclonal Antibodies. Principles and Applications, vol. 2, JR Birch, ES Lennox (eds), New York, John Wiley and Sons, 1995, pp 45-105

    Google Scholar 

  32. Schlom J: Monoclonal antibodies in cancer therapy. In Biologic Therapy of Cancer (2nd ed), Philadelphia, PA, J. B. Lippincott Co. 1995, pp 507-521

    Google Scholar 

  33. Jurcic JC, Scheinberg DA, Houghton AN: Monoclonal antibody therapy of cancer. In Cancer chemotherapy and Biological Response Modifiers, HM Pinedo, DL Longo, BA Chabner (eds); Amsterdam, Elsevier Science Publishers Annual 17, 1997, 1998, pp 195-216

    Google Scholar 

  34. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton J: Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial. Proceedings of ASCO 17:377, 1998

    Google Scholar 

  35. Mendelsohn J, Baselga J: Antibodies to growth factors and receptors. In Biologic Therapy of Cancer (2nd ed) 1995, pp 607-623

  36. Cheung N-K V, Lazarus H, Miraldi FD, Abramowsky CR, Kallie S, Saarinen UM, Spitzer T, Strandjord SE, Cocci PF, Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987

    Google Scholar 

  37. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, the German Cancer Aid 17-1A Study Group: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343: 1177-1183, 1994

    Google Scholar 

  38. Leget GA, Czuezman MS: Use of Rituximab, the new FDAapproved antibody. Curr Opin Oncol 10(6):548-551, 1998

    Google Scholar 

  39. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H: Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European study group of campath-1H treatment in low grade non-Hodgkin's lymphoma. J Clin Oncol 16:3257-3263, 1998

    Google Scholar 

  40. Jurcic JO, Caron PC, DeBlasio A, Dumont L, Warrell RP, Scheinberg DA: Targeted therapy with humanized anti-CD33 monoclonal antibody (HuM195) reduces residual disease in acute promyelocytic leukemia. Blood 86:517a, 1995

    Google Scholar 

  41. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF: Phase I trial of the murine monoclonal anti-GD2 antibody 14G9a in metastatic melanoma. Cancer Res 52:4342-4347, 1992

    Google Scholar 

  42. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C: Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother 17:151-180, 1995

    Google Scholar 

  43. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W: Randomized phase II study of BR96-Doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478-484, 1999

    Google Scholar 

  44. Kuan CT, Pai LH, Pastan L: Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: Relevance to vascular leak syndrome. Clin Cancer Res 1(12):1589-1594, 1995

    Google Scholar 

  45. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985

    Google Scholar 

  46. Livingston PO, Jones M, DeLeo AB, Oettgen HF, Old LJ: Serological response in stage II melanoma patients receiving allogeneic melanoma cell vaccines. Cancer 56:2194-2200, 1985

    Google Scholar 

  47. Livingston PO, Watanoabe T, Shiku H, Houghton AN, Albino A, Takahashi T, Resnick A, Michitsch R, Pinsky CM, Oettgen HF, Old LJ: Serological response of melanoma patients receiving melanoma cell vaccines, I. Autologous cultured melanoma cells. Int J Cancer 30:413-422, 1982

    Google Scholar 

  48. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettegen HF, Old LJ: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050, 1989

    Google Scholar 

  49. Helling F, Shang Y, Calves M, Oettgen HF, Livingston PO: Increased immunogenicity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 54:197-203, 1994

    Google Scholar 

  50. Helling F, Zhang A, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Oettgen HF, Livingston PO: GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788, 1995

    Google Scholar 

  51. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ, Marciani D: Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280, 1994

    Google Scholar 

  52. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO: Antibodies can eradicate cancer micrometastases. Cancer Res 58:2844-2849, 1998

    Google Scholar 

  53. Fung PYS, Madej M, Koganty RR, Longenecker BM: Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308-4314, 1990

    Google Scholar 

  54. Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC: Immunogenicity of the fucosyl-GM1-keyhole limpet hemocyanin (KLH) conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 5:2773-2779, 1999.

    Google Scholar 

  55. Maclean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, Longenecker BM: Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292-305, 1992

    Google Scholar 

  56. Adluri S, Helling F, Calves MJ, Lloyd KO, Livingston PO: Immunogenicity of synthetic TF-and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41: 185-192, 1995

    Google Scholar 

  57. MacLean GD, Reddish M, Koganty R, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM: Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36:215-222, 1993

    Google Scholar 

  58. Ragupathi G, Slovin S, Adluri S, Sames D, Kim I-J, Kim HM, Spassova M, Bornmann WG, Lloyd K, Scher HI, Livingston PO, Danishefsky SJ: A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle. Angewandte. Chemie 38:563-566, 1999

    Google Scholar 

  59. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI: Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 96:5710-5715, 1999

    Google Scholar 

  60. Livingston PO: Approaches to augmenting the immunogenicity of melanoma gangliosides. In From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147-166, 1995

    Google Scholar 

  61. Gilewski T, Adluri S, Zhang S, Ragupathi G, Houghton A, Norton L, Livingston PO: Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res, in press

  62. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO: Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85:659-666, 2000.

    Google Scholar 

  63. Itzkowitz S, Bloom EJ, Kokal WA, Modin G, Hakamori SI, Kim YS: Sialosyl Tn: a novel mucin antigen associated with prognosis in colorectal carcinoma patients. Cancer 66:1960-1966, 1990

    Google Scholar 

  64. MacLean GD, Reddish MA, Koganty RR, Longenecker BM: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic sTn vaccine. J Immunol 9:59-68, 1996

    Google Scholar 

  65. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287, 1999

    Google Scholar 

  66. DiFronzo LA, Morton DL: Melanoma vaccines: Overview of current status of clinical trials. Adv Oncol in press

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA

    Philip O. Livingston, Govindaswami Ragupathi & Cristina Musselli

Authors
  1. Philip O. Livingston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Govindaswami Ragupathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Musselli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Livingston, P.O., Ragupathi, G. & Musselli, C. Autoimmune and Antitumor Consequences of Antibodies Against Antigens Shared by Normal and Malignant Tissues. J Clin Immunol 20, 85–93 (2000). https://doi.org/10.1023/A:1006697728855

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006697728855

Search

Navigation